QIAGEN Welcomes U.S. Guidance for Latent TB Testing in Primary Care

Sep 08, 2016, 12:46 ET from QIAGEN N.V.

GERMANTOWN, Maryland, and HILDEN, Germany, September 8, 2016 /PRNewswire/ --

U.S. Preventive Services Task Force issues recommendations to screen high-risk patients 

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today welcomed recommendations issued by the U.S. Preventive Services Task Force (USPSTF) that primary care clinicians screen adult patients in groups at high risk for latent tuberculosis infection (LTBI), a condition that produces no symptoms but can progress to active tuberculosis, a highly contagious and potentially fatal disease. The final USPSTF recommendations refer to QIAGEN's QuantiFERON-TB® Gold (QFT®) as a test proven to be reliable in screening for latent TB infection and suggest that this class of test may be preferable in certain patient groups.

"The Task Force acknowledges tuberculosis as 'an important, preventable disease' in the United States and the new LTBI guidelines are unprecedented in that it expands the scope of testing to all providers, and calls upon primary care physicians to play a key role in ending tuberculosis in the United States." said Dr. Masae Kawamura, Senior Director of Medical and Scientific Affairs for QIAGEN. "Up to now, TB screening in the United States and most countries has been limited to public health programs, specialty physicians, and facilities under health regulations. The new directive of the USPSTF LTBI guidelines for primary care clinicians is truly an important step to eliminate tuberculosis in the US."

Click here for full press release

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={AADED7A0-48B4-4074-A732-0B25958209F3}&lang=en

Contacts: Public Relations: Dr. Thomas Theuringer Senior Director Public Relations +49-2103-29-11826 Email: pr@qiagen.com http://www.twitter.com/qiagen   https://www.facebook.com/QIAGEN pr.qiagen.com Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 Email: ir@qiagen.com ir.qiagen.com

SOURCE QIAGEN N.V.